Esta página foi traduzida automaticamente e a precisão da tradução não é garantida. Por favor, consulte o versão em inglês para um texto fonte.

A Study to Investigate the Efficacy and Safety of Alpha1H as a Neoadjuvant Therapy in Participants With Low- to Intermediate-Risk/Low-Grade Papillary Non-Muscle Invasive Bladder Cancer

31 de agosto de 2026 atualizado por: Hamlet Pharma AB

A Randomized Phase III Study to Investigate the Efficacy and Safety of Alpha1H as a Neoadjuvant Therapy in Participants With Low- to Intermediate-Risk/Low-Grade Papillary Non-Muscle Invasive Bladder Cancer

The goal of this clinical trial is to learn if the drug Alpha1H works to treat low-to-intermediate risk non-muscle-invasive bladder cancer in adults. It will also learn about the safety of drug Alpha1H.

The main questions it aims to answer are:

  • Does giving drug Alpha1H before surgery lower the risk of cancer returning or worsening compared to standard care alone?
  • Is drug Alpha1H safe and well-tolerated by participants? Researchers will compare participants receiving drug Alpha1H before standard surgery to participants receiving standard care alone to see if drug Alpha1H lowers the risk of cancer returning or progressing.

Participants will:

  • Be randomly assigned to receive either drug Alpha1H before surgery or standard care alone.
  • Receive drug Alpha1H directly into the bladder 6 times over about 1 month if assigned to the Alpha1H group.
  • Hold the liquid in the bladder for up to 2 hours during each visit.
  • Undergo standard surgery through the urethra (TURBT) to remove remaining tumor tissue.
  • Visit the clinic regularly for follow-up checkups (including bladder examinations and urine tests) to check if the cancer returns.
  • Fill out questionnaires about their quality of life.

Visão geral do estudo

Status

Ainda não está recrutando

Condições

Intervenção / Tratamento

Tipo de estudo

Intervencional

Inscrição (Estimado)

194

Estágio

  • Fase 3

Contactos e Locais

Esta seção fornece os detalhes de contato para aqueles que conduzem o estudo e informações sobre onde este estudo está sendo realizado.

Contato de estudo

Estude backup de contato

Locais de estudo

  • Tcheca
      • Prague, Tcheca, 15000
        • Fakultní nemocnice Motol a Homolka

Critérios de participação

Os pesquisadores procuram pessoas que se encaixem em uma determinada descrição, chamada de critérios de elegibilidade. Alguns exemplos desses critérios são a condição geral de saúde de uma pessoa ou tratamentos anteriores.

Critérios de elegibilidade

Idades elegíveis para estudo

  • Adulto
  • Adulto mais velho

Aceita Voluntários Saudáveis

Não

Descrição

Inclusion Criteria:

  • Signed and dated informed consent.
  • Low- or intermediate-risk non-muscle-invasive bladder cancer (NMIBC) meeting one of the following definitions:
  • Low-risk NMIBC: Primary, solitary, Ta, low-grade, 0.5 cm to 3 cm.
  • Intermediate-risk NMIBC (low-to-intermediate risk subgroup per IBCG classification):
  • Primary multifocal (<10 lesions), Ta, low-grade, 0.5 cm to 3 cm;
  • Recurrent solitary, Ta, low-grade, 0.5 cm to 3 cm; or
  • Recurrent multifocal (<10 lesions), Ta, low-grade, >1 year after previous recurrence.
  • Men and women aged 18 years or older.
  • Negative pregnancy test at screening for women of childbearing potential.
  • Women of childbearing potential must agree to use highly effective contraception methods throughout study participation; men of childbearing potential must refrain from donating sperm during the study.
  • Ability to retain bladder contents for 2 hours.

Exclusion Criteria:

  • Patient with non-papillary tumor appearance at the time of initial cystoscopy.
  • Previous history of T1 or high-grade disease in recurrent tumors.
  • Patients with T1 or high-grade non-muscle invasive papillary bladder cancer (NMIBC).
  • Previous intravesical BCG immunotherapy.
  • Patients with any other cancer diagnosis within the last 5 years (except for skin basalioma).
  • Acute urinary tract infection requiring antibiotic treatment.
  • Prior radiotherapy or systemic chemotherapy.
  • WHO performance status of 3 or 4.
  • Any other investigational agent or non-marketed product within one month prior to Visit 1 and during the trial.
  • Known active HIV infection, defined as detectable HIV viral load at screening.
  • Active hepatitis B virus (HBV) infection, defined as hepatitis B surface antigen (HBsAg) positivity with detectable HBV DNA at screening.
  • Active hepatitis C virus (HCV) infection, defined as anti-HCV antibody positivity with detectable HCV RNA at screening in a patient not on stable antiviral treatment.
  • Any concurrent illness that may render a participant ineligible or limit compliance with study requirements.
  • Previously enrolled in this trial.

Plano de estudo

Esta seção fornece detalhes do plano de estudo, incluindo como o estudo é projetado e o que o estudo está medindo.

Como o estudo é projetado?

Detalhes do projeto

  • Finalidade Principal: Tratamento
  • Alocação: Randomizado
  • Modelo Intervencional: Atribuição Paralela
  • Mascaramento: Nenhum (rótulo aberto)

Armas e Intervenções

Grupo de Participantes / Braço
Intervenção / Tratamento
Experimental: Alpha1H
Participants receive 6 intravesical instillations of Alpha1H over approximately 1 month prior to transurethral resection of bladder tumor (TURBT).
Medicamento: Alpha1H
Administered via intravesical instillation directly into the urinary bladder. Participants in the experimental group receive a total of 6 instillations on Days 1, 3, 5, 8, 15, and 22 over approximately 1 month prior to TURBT. During each treatment, participants are asked to retain the solution in the bladder for up to 2 hours.
Procedimento: Transurethral Resection of Bladder Tumor (TURBT)
Standard endoscopic surgical procedure performed through the urethra to resect and remove papillary bladder tumor tissue. Performed approximately 30 days after study entry (on Visit 8). Resected tumor tissue is collected for histopathology and central analysis.
Medicamento: Intravesical Chemotherapy
A single early intravesical instillation of standard-of-care chemotherapy (epirubicin, mitomycin, or gemcitabine) administered into the urinary bladder shortly following TURBT surgery in accordance with local institutional guidelines.
Comparador Ativo: Standard of Care
Participants receive standard of care consisting of transurethral resection of bladder tumor (TURBT) followed by a single early intravesical instillation of standard chemotherapy.
Procedimento: Transurethral Resection of Bladder Tumor (TURBT)
Standard endoscopic surgical procedure performed through the urethra to resect and remove papillary bladder tumor tissue. Performed approximately 30 days after study entry (on Visit 8). Resected tumor tissue is collected for histopathology and central analysis.
Medicamento: Intravesical Chemotherapy
A single early intravesical instillation of standard-of-care chemotherapy (epirubicin, mitomycin, or gemcitabine) administered into the urinary bladder shortly following TURBT surgery in accordance with local institutional guidelines.

O que o estudo está medindo?

Medidas de resultados primários

Medida de resultado
Prazo
Event-Free Survival (EFS)
Prazo: From randomization until the occurrence of an EFS event or study completion, assessed at 3, 6, 9 (optional), and 12 months post-randomization, and every 6 months thereafter for up to 3 years.
From randomization until the occurrence of an EFS event or study completion, assessed at 3, 6, 9 (optional), and 12 months post-randomization, and every 6 months thereafter for up to 3 years.

Medidas de resultados secundários

Medida de resultado
Descrição da medida
Prazo
Complete Response (CR) Rate
Prazo: Day 30 (±5 days), prior to TURBT
Day 30 (±5 days), prior to TURBT
Overall Survival (OS)
Prazo: From randomization through study completion (assessed at 3, 6, 9 [optional], and 12 months, and every 6 months thereafter for up to 3 years).
From randomization through study completion (assessed at 3, 6, 9 [optional], and 12 months, and every 6 months thereafter for up to 3 years).
Tumor Response (Morphological and Cellular)
Prazo: Baseline (Day 1) to Day 30 (±5 days)
Assessed as: (1) change in papillary tumor size (% reduction from baseline); (2) tumor cell shedding in urine (cells/mL); (3) apoptosis in shed cells (% TUNEL-positive cells); (4) Alpha1H uptake in shed cells (% Alpha1H-positive cells). Each parameter reported separately.
Baseline (Day 1) to Day 30 (±5 days)
Tumor Gene Expression
Prazo: Baseline (Day 1) to Day 30 (±5 days)
Assessed by RNA sequencing (whole transcriptome) in tumor tissue and urine RNA. Reported as number of differentially expressed cancer-related genes and pathways between the Alpha1H and SOC arms.
Baseline (Day 1) to Day 30 (±5 days)
Urinary Biomarkers and Immune Response
Prazo: Day 1, 3, 5, 8, 15, and 22 (pre- and post-instillation), and Day 30 (±5 days)
Assessed by proteomic profiling of urine samples. Reported as change in concentration (pg/mL) of cytokines, chemokines, and interferons between pre- and post-instillation samples, compared between the Alpha1H and SOC arms.
Day 1, 3, 5, 8, 15, and 22 (pre- and post-instillation), and Day 30 (±5 days)
Incidence and Severity of Adverse Events (AEs)
Prazo: From Visit 1 (Screening) through Visit 9 (Day 40/50) and follow-up period (up to 3 years)
From Visit 1 (Screening) through Visit 9 (Day 40/50) and follow-up period (up to 3 years)
Change in Quality of Life (QoL) as Assessed by the QLQ-NMIBC24 Questionnaire
Prazo: From Visit 1 (Screening) through follow-up visits (up to 3 years)
Quality of life will be assessed using the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire - Non-Muscle-Invasive Bladder Cancer Module (EORTC QLQ-NMIBC24), a 24-item, disease-specific patient-reported outcome instrument. Each domain score is linearly transformed to range from 0 to 100. On functional scales (e.g., sexual function), higher scores indicate better functioning; on symptom-related scales (e.g., urinary symptoms, future perspective), higher scores indicate greater symptom burden. Scores are calculated per the EORTC scoring manual.
From Visit 1 (Screening) through follow-up visits (up to 3 years)

Colaboradores e Investigadores

É aqui que você encontrará pessoas e organizações envolvidas com este estudo.

Patrocinador

Hamlet Pharma AB

Datas de registro do estudo

Essas datas acompanham o progresso do registro do estudo e os envios de resumo dos resultados para ClinicalTrials.gov. Os registros do estudo e os resultados relatados são revisados ​​pela National Library of Medicine (NLM) para garantir que atendam aos padrões específicos de controle de qualidade antes de serem publicados no site público.

Datas Principais do Estudo

Início do estudo (Estimado)

1 de setembro de 2026

Conclusão Primária (Estimado)

1 de julho de 2029

Conclusão do estudo (Estimado)

1 de julho de 2029

Datas de inscrição no estudo

Enviado pela primeira vez

26 de agosto de 2026

Enviado pela primeira vez que atendeu aos critérios de CQ

31 de agosto de 2026

Primeira postagem (Real)

4 de setembro de 2026

Atualizações de registro de estudo

Última Atualização Postada (Real)

4 de setembro de 2026

Última atualização enviada que atendeu aos critérios de controle de qualidade

31 de agosto de 2026

Última verificação

1 de agosto de 2026

Mais Informações

Termos relacionados a este estudo

Palavras-chave

Termos MeSH relevantes adicionais

Outros números de identificação do estudo

  • HP003-001
  • 2026-525531-16-00 (Ctis)

Plano para dados de participantes individuais (IPD)

Planeja compartilhar dados de participantes individuais (IPD)?

INDECISO

Informações sobre medicamentos e dispositivos, documentos de estudo

Estuda um medicamento regulamentado pela FDA dos EUA

Sim

Estuda um produto de dispositivo regulamentado pela FDA dos EUA

Não

Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .

Se inscrever